253 related articles for article (PubMed ID: 10740644)
21. [Evaluation of severe side effects of high-dose methotrexate in osteosarcoma].
Umeda T; Takada N; Hodaka E; Endoh F; Ishii T
Gan To Kagaku Ryoho; 1984 Feb; 11(2):285-94. PubMed ID: 6582805
[TBL] [Abstract][Full Text] [Related]
22. [Management of the administration of leucovorin calcium in high-dose methotrexate therapy].
Kickinger W; Ritschl P; Kotz R
Arzneimittelforschung; 1989 Jun; 39(6):728-31. PubMed ID: 2789050
[TBL] [Abstract][Full Text] [Related]
23. [Studies on the effect of high-dose methotrexate-citrovorum factor treatment for 89Sr induced osteosarcoma in mice (author's transl)].
Nakamura T
Nihon Seikeigeka Gakkai Zasshi; 1982 Feb; 56(2):149-61. PubMed ID: 6978919
[TBL] [Abstract][Full Text] [Related]
24. Significance of the 48-hour plasma level in high-dose methotrexate regimens.
Perez C; Wang YM; Sutow WW; Herson J
Cancer Clin Trials; 1978; 1(2):107-11. PubMed ID: 316368
[TBL] [Abstract][Full Text] [Related]
25. High leucovorin doses during high-dose methotrexate treatment may reduce the cure rate in childhood acute lymphoblastic leukemia.
Skärby TV; Anderson H; Heldrup J; Kanerva JA; Seidel H; Schmiegelow K;
Leukemia; 2006 Nov; 20(11):1955-62. PubMed ID: 16990760
[TBL] [Abstract][Full Text] [Related]
26. Phase II clinical trial with high-dose methotrexate therapy and citrovorum factor rescue.
Isacoff WH; Eilber F; Tabbarah H; Klein P; Dollinger M; Lemkin S; Sheehy P; Cone L; Rosenbloom B; Sieger L; Block JB
Cancer Treat Rep; 1978 Sep; 62(9):1295-304. PubMed ID: 356984
[TBL] [Abstract][Full Text] [Related]
27. [EEG-slowing after high-dose Methotrexate with citrovorumfactor-rescue. A spectralanalytic study (author's transl)].
Korinthenberg R; Lütkenhöner B; Palm D; Ritter J
EEG EMG Z Elektroenzephalogr Elektromyogr Verwandte Geb; 1982 Mar; 13(1):22-7. PubMed ID: 6806066
[TBL] [Abstract][Full Text] [Related]
28. Variability in dose intensity of high-dose methotrexate for nonmetastatic osteosarcoma.
Leavey PJ; Mantadakis E; Maale G
Pediatr Hematol Oncol; 2002; 19(7):483-9. PubMed ID: 12217194
[TBL] [Abstract][Full Text] [Related]
29. Methotrexate levels and outcome in osteosarcoma.
Zelcer S; Kellick M; Wexler LH; Shi W; Sankaran M; Lo S; Healey J; Huvos AG; Meyers PA; Gorlick R
Pediatr Blood Cancer; 2005 Jun; 44(7):638-42. PubMed ID: 15704189
[TBL] [Abstract][Full Text] [Related]
30. [Preliminary evaluation of individualized use of large doses of methotrexate for treatment of osteosarcoma in children and adolescents].
Perek D; Jurczyk-Procyk S; Prokopczyk J; Piekarczyk A; Zelazowski J; Dembowska-Bagińska B; Wieckowska J; Witkowska-Ozogowska J; Kozera M
Pediatr Pol; 1995 Nov; 70(11):929-37. PubMed ID: 8677159
[TBL] [Abstract][Full Text] [Related]
31. Carboxypeptidase-G2 rescue in a patient with high dose methotrexate-induced nephrotoxicity.
Widemann BC; Hetherington ML; Murphy RF; Balis FM; Adamson PC
Cancer; 1995 Aug; 76(3):521-6. PubMed ID: 8625136
[TBL] [Abstract][Full Text] [Related]
32. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma.
Crews KR; Liu T; Rodriguez-Galindo C; Tan M; Meyer WH; Panetta JC; Link MP; Daw NC
Cancer; 2004 Apr; 100(8):1724-33. PubMed ID: 15073863
[TBL] [Abstract][Full Text] [Related]
33. Transient cerebral dysfunction following chemotherapy for osteogenic sarcoma.
Allen JC; Rosen G
Ann Neurol; 1978 May; 3(5):441-4. PubMed ID: 310278
[TBL] [Abstract][Full Text] [Related]
34. Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy.
Bacci G; Ferrari S; Longhi A; Forni C; Loro L; Beghelli C; Tremosini M; Versari M
Oncol Rep; 2003; 10(4):851-7. PubMed ID: 12792734
[TBL] [Abstract][Full Text] [Related]
35. [Successful treatment of high-dose methotrexate-induced oliguric acute renal failure by using a combination of hemodialysis filtration and direct hemoperfusion].
Morozumi I; Inagaki A; Suzuki S; Sato Y; Ogura H; Suga N; Komatsu H; Wakita A; Yamada K
Gan To Kagaku Ryoho; 2015 May; 42(5):609-11. PubMed ID: 25981656
[TBL] [Abstract][Full Text] [Related]
36. Population pharmacokinetics of high-dose methotrexate after intravenous administration in pediatric patients with osteosarcoma.
Colom H; Farré R; Soy D; Peraire C; Cendros JM; Pardo N; Torrent M; Domenech J; Mangues MA
Ther Drug Monit; 2009 Feb; 31(1):76-85. PubMed ID: 19077931
[TBL] [Abstract][Full Text] [Related]
37. Successful desensitization to high-dose methotrexate after systemic anaphylaxis.
Davis KA; Williams P; Walker JC
Ann Allergy Asthma Immunol; 2003 Jan; 90(1):87-9. PubMed ID: 12546343
[TBL] [Abstract][Full Text] [Related]
38. Acral erythema caused by high-dose methotrexate therapy in patients with osteogenic sarcoma.
Postovsky S; Ben Arush MW
Pediatr Hematol Oncol; 2005 Mar; 22(2):167-73. PubMed ID: 15805003
[TBL] [Abstract][Full Text] [Related]
39. Leukoencephalopathy following high-dose iv methotrexate chemotherapy with leucovorin rescue.
Allen JC; Rosen G; Mehta BM; Horten B
Cancer Treat Rep; 1980; 64(12):1261-73. PubMed ID: 6970616
[TBL] [Abstract][Full Text] [Related]
40. Effective removal of methotrexate by high-flux hemodialysis.
Saland JM; Leavey PJ; Bash RO; Hansch E; Arbus GS; Quigley R
Pediatr Nephrol; 2002 Oct; 17(10):825-9. PubMed ID: 12376811
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
